Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vanuatu Health Times.
Press releases published on January 20, 2026
January 20, 2026
Global Virus Network Warns Measles Resurgence
Indeterminate
GlobeNewswire
January 20, 2026
New Research Reveals Key Quality of Life Insights in ADHD Management
Indeterminate
GlobeNewswire
January 20, 2026
ACGME Announces Request for Grant Proposals for Back to Bedside Project Funding
Indeterminate
GlobeNewswire
January 20, 2026
New Jersey Overdose Deaths Fall to Lowest Level in Years, Outpacing National Declines
Indeterminate
GlobeNewswire
January 20, 2026
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
Indeterminate
GlobeNewswire
January 20, 2026
WellSpan’s nationally-recognized MyWellSpan patient portal and application surpasses 1 million users
Indeterminate
GlobeNewswire
January 20, 2026
NAHQ and Joint Commission Launch Regulatory & Accreditation Micro-Credential to Advance Quality and Patient Safety
Indeterminate
GlobeNewswire
January 20, 2026
Rentschler Biopharma Announces Executive Board Changes and Next Phase of Corporate Strategy
Indeterminate
GlobeNewswire
January 20, 2026
AskLuci.io Releases Whitepaper Examining Hidden Administrative Work Costing Allied Health Clinics More Than Money
Indeterminate
GlobeNewswire
January 20, 2026
Comfort Keepers Ireland Highlights Urgent Need for Scaling Safe, Regulated Home Support
Indeterminate
GlobeNewswire
January 20, 2026
Adaptin Bio Advances Novel Brain Cancer Treatment Candidate Towards Phase 1 Glioblastoma Clinical Trial
Indeterminate
GlobeNewswire
January 20, 2026
First-of-its-kind Trojan Horse Cancer Treatment Approved for Clinical Trials
Indeterminate
GlobeNewswire
January 20, 2026
Methyl Cellulose Market worth $5.88 billion by 2030, at a CAGR of 10.0%, says MarketsandMarkets™
Indeterminate
GlobeNewswire
January 20, 2026
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
Indeterminate
GlobeNewswire